Cyclerion Therapeutics Inc.
| NASDAQ: CYCN | Healthcare / Biotechnology / USA |
| 2.49 | +0.3066 | +14.06% | Vol 72.31K | 1Y Perf 147.53% |
| Dec 1st, 2023 15:59 DELAYED |
| BID | 2.38 | ASK | 3.25 | ||
| Open | 2.33 | Previous Close | 2.18 | ||
| Pre-Market | - | After-Market | 2.38 | ||
| - - | -0.11 -4.29% |
| Target Price | 4.00 | Analyst Rating | — 0.00 | |
| Potential % | 60.86 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 45.43 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.11 | Earnings Rating | — | |
| Market Cap | 6.08M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.32 | |
| Beta | 1.82 |
Today's Price Range 2.273.28 | 52W Range 1.7519.66 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 21.93% | ||
| 1 Month | 0.67% | ||
| 3 Months | -30.35% | ||
| 6 Months | -42.84% | ||
| 1 Year | 147.53% | ||
| 3 Years | -18.74% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -135.40 | |||
ROE last 12 Months | -130.67 | |||
ROA (5Y Avg) | -68.93 | |||
ROA last 12 Months | -102.67 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -130.67 | |||
Return on invested Capital Q | -50.12 | |||
Return on invested Capital Y | -20.60 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 1.66 | ||||
| 87.13 | ||||
| - | ||||
| -0.80 | ||||
| -0.97 | ||||
| 1.66 | ||||
| 0.38 | ||||
| -26 450 900.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.40 | ||||
| 2.50 | ||||
| 0.44 | ||||
| 0.00 | ||||
| -47 636.00 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -10 162.60 | ||||
| -10 139.00 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 297.00K | ||||
| 0.01 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -1.83 | - |
| Q01 2023 | - | -0.16 | - |
| Q04 2022 | - | -0.16 | - |
| Q03 2022 | -0.35 | -0.24 | 31.43 |
| Q02 2022 | -0.34 | -0.31 | 8.82 |
| Q01 2022 | -0.36 | -0.30 | 16.67 |
| Q04 2021 | -0.32 | -0.24 | 25.00 |
| Q03 2021 | -0.29 | -0.26 | 10.34 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 72.31K |
| Shares Outstanding | 2.45K |
| Shares Float | 1.30M |
| Trades Count | 658 |
| Dollar Volume | 193.11K |
| Avg. Volume | 4.70K |
| Avg. Weekly Volume | 3.59K |
| Avg. Monthly Volume | 4.18K |
| Avg. Quarterly Volume | 6.32K |
Cyclerion Therapeutics Inc. (NASDAQ: CYCN) stock closed at 2.4866 per share at the end of the most recent trading day (a 14.06% change compared to the prior day closing price) with a volume of 72.31K shares and market capitalization of 6.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 34 people. Cyclerion Therapeutics Inc. CEO is Peter M. Hecht.
The one-year performance of Cyclerion Therapeutics Inc. stock is 147.53%, while year-to-date (YTD) performance is 278.94%. CYCN stock has a five-year performance of %. Its 52-week range is between 1.7501 and 19.664, which gives CYCN stock a 52-week price range ratio of 4.11%
Cyclerion Therapeutics Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 1.66, a price-to-sale (PS) ratio of 87.13, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -102.67%, a ROC of -130.67% and a ROE of -130.67%. The company’s profit margin is -%, its EBITDA margin is -10 139.00%, and its revenue ttm is $297.00 Thousand , which makes it $0.01 revenue per share.
Of the last four earnings reports from Cyclerion Therapeutics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclerion Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cyclerion Therapeutics Inc. is — (0), with a target price of $4, which is +60.86% compared to the current price. The earnings rating for Cyclerion Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclerion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclerion Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.54, ATR14 : 0.36, CCI20 : 175.05, Chaikin Money Flow : -0.36, MACD : -0.20, Money Flow Index : 77.09, ROC : 13.03, RSI : 51.17, STOCH (14,3) : 48.14, STOCH RSI : 1.00, UO : 44.41, Williams %R : -51.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclerion Therapeutics Inc. in the last 12-months were:
Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
CEO: Peter M. Hecht
Telephone: +1 857 327-8778
Address: 301 Binney Street, Cambridge 02142, MA, US
Number of employees: 34
